Opportunities of Amlodipine as a Potential Candidate in the Evaluation of Drug Compliance during Antihypertensive Therapy

Background and Objectives: Blood pressure measurement is essential evidence to establish that the chosen medicine and dosage are appropriate, and also indirectly indicates whether the medicine is being used at all. Therefore, current research compares adherence to the target blood pressure at home and in the hospital between different age groups, using similar combinations of the drugs prescribed by the doctor within ongoing antihypertensive therapy. Moreover, it is very important to develop a method for the determination of amlodipine and its metabolite, which would suitable for clinical applications, when the result is needed as quick as possible. Materials and Methods: This prospective study included patients aged ≥18 years who were diagnosed with hypertension. Subjects were divided into two age groups according to European Society of Cardiology (ESC) hypertension guidelines; older patients (≥65 years) and adult patients (publishersversionPeer reviewe

Relationship between intravascular ultrasound tissue characterization of infarct related artery, circulating atherosclerosis biomarkers and disease course in STEMI patients

Anotācija ST elevāciju miokarda infarkta gadījumā (STEMI) patofizioloģiskais substrāts ir rupturējusi vai erodējusi panga un tromboze. Šajā darbā veicām iMap IVUS audu analīzi STEMI mērķa bojājumiem 75 pacientiem, noteicām asinīs aterosklerozes biomarķierus un veicām 10 mēnešu apsekojumu. Mūsu rezultāti parādīja augstu nekrotisko audu daudzumu mērķa bojājumā un augstu, bet salīdzinoši zemāku, proksimālajā segmentā. Proksimālajā segmentā 10 mēnešu laikā samazinājās lipīdu audu daudzums par 10,2%. Neointimai 10 mēnešus pēc stenta implantācijas bija raksturīgs stabilāks audu sastāvs pēc iMap IVUS nekā natīvai aterosklerotiskai pangai šajā artērijā. Asins aterosklerozes biomarķieru saistību ar pangas nekrotiskajiem audiem neatradām. Kardiogēna šoka un kardiālā nāvē mirušo STEMI slimnieku mērķa bojājums saturēja vairāk kalcija. Atslēgas vārdi: iMap intravaskulārā ultraskaņa, ST elevāciju miokarda infarkts, aterosklerozes asins biomarķieri, neoaterosklerozeAbstract STEMI pathophysiological substrate is ruptured or eroded atherosclerotic plaque. In current study we evaluated culprit lesions with iMap IVUS tissue characterization and atherosclerosis blood biomarkers in 75 STEMI patients in acute setting and ten months later. Our results showed high percentage of necrotic tissue in culprit lesion. Comparatively lower, but still high percentage of necrotic tissue was also observed in proximal segment. We observed 10.2% decrease in lipidic tissue at ten months follow-up. Neointimal tissue characterisation showed more stable pattern in comparison with native atherosclerosis 10 months after stent implantation. We did not find correlation between biomarkers and necrotic tissue in culprit lesion. Cardiogenic shock and cardiac death patients had a higher percentage of calcific tissue in the culprit lesion. Key words: iMap intravascular ultrasound, STEMI, atherosclerosis blood biomarkers, neoatherosclerosi

Wytyczne ESC/ESH dotyczace postȩpowania w nadciśnieniu tȩtniczym (2018) : Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Nadciśnienia Tȩtniczego (ESH) do spraw postȩpowania w nadciśnieniu tȩtniczym

2018 ESC/ESH Guidelines for the management of arterial hypertensionpublishersversionPeer reviewe

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME

2018 ESC/ESH Guidelines for the management of arterial hypertension

No abstract available

2018 ESC/ESH Guidelines for the management of arterial hypertension

International audienc